Novo Nordisk A/S

Equities

NOVO B

DK0062498333

Pharmaceuticals

Real-time Estimate Cboe Europe 09:11:43 2024-06-06 am EDT 5-day change 1st Jan Change
967.6 DKK +3.35% Intraday chart for Novo Nordisk A/S +5.61% +38.71%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Novo Nordisk braces for Ozempic rivals in China RE
European equities gain on tech boost in run-up to ECB RE
Novo Nordisk Faces Competition in China for Key Ingredient in Diabetes, Weight Loss Drug MT
Chinese drugmakers developing generic drugs of Novo Nordisk's Ozempic RE
Novo Nordisk braces for generic challenge to Ozempic, Wegovy in China RE
Health Care Climbs on Obesity-Drug Bets - Health Care Roundup DJ
UK Stocks-Factors to watch on June 6 RE
UK Institute Makes Draft Recommendation for Eli Lilly's Weight-loss Drug With No Time Limit MT
Britain considers offering Lilly weight-loss drug on better terms than Wegovy RE
Adocia appoints Director of Operations CF
Structure Therapeutics' obesity drug meets main goal in mid-stage study RE
JPMorgan European G&I raises dividend after outperforming benchmark AN
Zealand Pharma Secures EU Panel Backing for Severe Hypoglycemia Treatment MT
Danish Government Implements Stricter Subsidy Rules for Diabetes Drugs MT
Wegovy maker Novo Nordisk sues nine spas, clinics and pharmacies over copycat drugs RE
NOVO NORDISK : Buy rating by Goldman Sachs ZD
EARNINGS AND TRADING: First Tin "consolidates" holdings in Taronga AN
Catalent Shareholders Approve Deal With Novo Holdings MT
Catalent stockholders approve deal with Novo Holdings RE
Sector Update: Health Care Stocks Fall Late Afternoon MT
Annual sales of weight-loss drugs seen hitting $150 billion RE
Sector Update: Health Care Stocks Retreat Tuesday Afternoon MT
Novo Nordisk Tells US Senate Health Committee Chair Sanders It Only Keeps 60% of Ozempic, Wegovy List Price MT
Novo Nordisk's Boost to Danish Employment Levels More than Expected, Economic Councils Says MT
Novo Nordisk Said to Defend Drug Prices Amid Heat from US Lawmakers MT
Chart Novo Nordisk A/S
More charts
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows: - diabetes and obesity treatment products (92.6%); - rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc. Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
936.2 DKK
Average target price
920 DKK
Spread / Average Target
-1.73%
Consensus
  1. Stock Market
  2. Equities
  3. NOVO B Stock
  4. News Novo Nordisk A/S
  5. Novo Nordisk Building Under Construction at Manufacturing Hub in Denmark Hit by Fire